Profile data is unavailable for this security.
About the company
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases and drive more durable responses. It is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, NVL-520, is being developed for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, NVL-655, is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC. LC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor.
- Revenue in USD (TTM)0.00
- Net income in USD-145.51m
- Incorporated2017
- Employees106.00
- LocationNuvalent IncOne Broadway, 14th FloorCAMBRIDGE 02142United StatesUSA
- Phone+1 (857) 357-7000
- Fax+1 (302) 655-5049
- Websitehttps://www.nuvalent.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immunitybio Inc | 302.00k | -600.96m | 4.12bn | 628.00 | -- | -- | -- | 13,648.16 | -1.05 | -1.05 | 0.0005 | -1.02 | 0.0008 | -- | 0.1677 | 480.89 | -161.65 | -112.76 | -946.50 | -316.07 | -- | -- | -199,138.70 | -37,700.74 | -- | -1.93 | 5.32 | -- | 159.17 | 67.62 | -40.00 | -- | 18.48 | -- |
| Alkermes Plc | 1.73bn | 599.95m | 4.15bn | 2.10k | 7.00 | 3.30 | 6.24 | 2.40 | 3.50 | 2.53 | 10.05 | 7.42 | 0.8532 | 1.32 | 5.81 | 821,991.40 | 29.65 | 1.34 | 38.77 | 1.74 | 85.31 | 83.32 | 34.76 | 2.12 | 2.77 | -- | 0.1878 | 0.00 | 49.61 | 8.74 | 1,665.99 | -- | -7.10 | -- |
| Alvotech SA | 114.39m | -494.28m | 4.25bn | 999.00 | -- | -- | -- | 37.18 | -2.05 | -2.05 | 0.4909 | -2.47 | 0.117 | 1.69 | 1.97 | 114,507.50 | -50.54 | -- | -63.82 | -- | -23.89 | -- | -432.09 | -- | 0.8107 | -1.26 | 2.49 | -- | 9.84 | -- | -7.43 | -- | -- | -- |
| Nuvalent Inc | 0.00 | -145.51m | 5.02bn | 106.00 | -- | 7.43 | -- | -- | -2.41 | -2.41 | 0.00 | 10.47 | 0.00 | -- | -- | 0.00 | -24.88 | -- | -26.01 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -54.20 | -- | -- | -- |
| Krystal Biotech Inc | 95.95m | 57.16m | 5.08bn | 229.00 | 94.46 | 6.35 | 80.05 | 52.91 | 1.88 | 1.88 | 3.38 | 28.02 | 0.1385 | -- | -- | 418,991.30 | 8.25 | -11.50 | 8.78 | -12.01 | 94.25 | -- | 59.57 | -492.85 | 12.42 | -- | 0.00 | -- | -- | -- | 107.81 | -- | 39.49 | -- |
| Apellis Pharmaceuticals Inc | 524.07m | -417.27m | 5.10bn | 702.00 | -- | 19.10 | -- | 9.73 | -3.46 | -3.46 | 4.33 | 2.20 | 0.5788 | 0.5747 | 3.50 | 746,538.40 | -46.09 | -73.88 | -57.28 | -90.03 | 86.47 | -- | -79.62 | -326.49 | 3.02 | -39.71 | 0.6087 | -- | 425.83 | -- | 18.94 | -- | -- | -- |
| Hims & Hers Health Inc | 959.40m | -2.35m | 5.10bn | 1.05k | -- | 14.78 | 633.84 | 5.32 | -0.0145 | -0.0145 | 4.46 | 1.61 | 2.33 | 6.68 | 176.36 | 917,209.40 | -0.5704 | -- | -0.6968 | -- | 82.41 | -- | -0.245 | -- | 2.48 | -- | 0.00 | -- | 65.49 | -- | 64.15 | -- | -- | -- |
| BridgeBio Pharma Inc | 218.60m | -538.26m | 5.21bn | 550.00 | -- | -- | -- | 23.85 | -3.23 | -3.23 | 1.29 | -5.61 | 0.2964 | -- | -- | 397,449.10 | -74.13 | -72.44 | -90.19 | -89.72 | 98.91 | 94.41 | -250.09 | -1,225.66 | -- | -11.48 | 2.53 | -- | -88.02 | -- | -33.67 | -- | -40.94 | -- |
| Organon & Co | 6.35bn | 1.05bn | 5.25bn | 10.00k | 5.00 | 108.74 | 4.06 | 0.8266 | 4.08 | 4.08 | 24.71 | 0.1876 | 0.5603 | 2.18 | 4.24 | 634,700.00 | 9.24 | 16.53 | 11.79 | 20.97 | 59.04 | 65.12 | 16.50 | 26.79 | 1.15 | 2.36 | 0.9945 | 8.25 | 1.44 | -8.52 | 11.56 | -13.83 | 20.72 | -- |
| Viking Therapeutics Inc | 0.00 | -93.72m | 5.74bn | 28.00 | -- | 6.14 | -- | -- | -0.9305 | -0.9305 | 0.00 | 8.47 | 0.00 | -- | -- | 0.00 | -16.76 | -21.91 | -17.52 | -23.04 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.73 | -- | -- | -- |
| Summit Therapeutics Inc | 0.00 | -116.03m | 5.89bn | 105.00 | -- | 133.22 | -- | -- | -0.1657 | -0.1657 | 0.00 | 0.063 | 0.00 | -- | -- | 0.00 | -53.76 | -77.32 | -59.38 | -86.35 | -- | -- | -- | -20,989.46 | -- | -118.81 | 0.6934 | -- | -100.00 | -- | -680.54 | -- | -4.84 | -- |
| Madrigal Pharmaceuticals Inc | 0.00 | -444.28m | 5.92bn | 376.00 | -- | 6.75 | -- | -- | -23.08 | -23.08 | 0.00 | 41.13 | 0.00 | -- | -- | 0.00 | -62.81 | -62.09 | -73.92 | -74.81 | -- | -- | -- | -- | 9.39 | -- | 0.1201 | -- | -- | -- | -26.50 | -- | 132.01 | -- |
| Ionis Pharmaceuticals Inc | 776.62m | -384.77m | 5.93bn | 927.00 | -- | 19.99 | -- | 7.64 | -2.67 | -2.67 | 5.40 | 2.03 | 0.275 | 0.379 | 81.52 | 837,777.80 | -13.62 | -6.30 | -15.20 | -7.44 | 98.72 | 98.75 | -49.54 | -21.23 | 7.28 | -- | 0.8114 | -- | 34.10 | 5.60 | -35.80 | -- | 11.83 | -- |
Data as of Jun 14 2024. Currency figures normalised to Nuvalent Inc's reporting currency: US Dollar USD
47.86%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 8.79m | 14.87% |
| Paradigm BioCapital Advisors LPas of 31 Mar 2024 | 4.18m | 7.07% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 3.33m | 5.64% |
| Perceptive Advisors LLCas of 31 Mar 2024 | 2.78m | 4.71% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.01m | 3.40% |
| Fairmount Funds Management LLCas of 31 Mar 2024 | 1.92m | 3.26% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.51m | 2.56% |
| Commodore Capital LPas of 31 Mar 2024 | 1.49m | 2.52% |
| Darwin Global Management Ltd.as of 31 Mar 2024 | 1.44m | 2.43% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 839.42k | 1.42% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
